Efficacy of dienogest treatment of clinical symptoms of rectovaginal endometriosis

Česká verzia

Authors: Z. Papíková; R. Hudeček; P. Ventruba; M. Szypulová
Authors place of work: Gynekologicko-porodnická klinika LF MU a FN, Brno, přednosta prof. MUDr. P. Ventruba, DrSc., MBA
Published in the journal: Ceska Gynekol 2019; 84(5): 331-336
Category:

Summary

Objective: The aim of this prospective, unicentric, cohort study was to evaluate the effect of dienogest use in the therapy of symptomatic endometriosis of rectovaginal septum in patients of fertile age.

Study design: Prospective, unicentric, cohort study.

Setting: Department of Obstetrics and Gynaecology, Brno University Hospital and Masaryk University Medical School, Brno.

Material and methods: Prospective analysis of the group of 32 patients in reproductive age who have previously been diagnosed with endometriosis of rectovaginal septum. These patients were treated conservatively with dienogest 2 mg per day during a 24-week period. Through questionnaires and clinical assessment, we have studied the presence of symptoms like dyspareunia, diffuse pelvic pain, Biberoglu-Behrman(B-B) score assessment and subjective pain perception using Visual Analogue Scale (VAS) of pain. Data were collected at the beginning of therapy, after 4, 12 and 24 weeks of dienogest use.

Results: Continual use of dienogest during the 24-week period diminishes symptoms of dyspareunia by 62% (p < 0.001), diffuse pelvic pain by 44% (p = 0,001), mean B-B score by 5.31 points and median VAS scale of 20 points (p < 0.001) in patients with a rectovaginal form of endometriosis.

Conclusion: We proved that continuous therapy of 2 mg of dienogest daily in the 24-week period is effective in reducing clinical symptoms like dyspareunia and diffuse pelvic pain in patients with endometriosis of rectovaginal septum during their reproductive age.

Keywords:

Endometriosis – rectovaginal septum – dyspareunia – pelvic pain – dienogest

Zdroje

1. Abrao, MS., Goncalves, MO., Dias, JA. Jr., et al. Comparison between clinical examination, trasnvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis. Hum Reprod, 2007, 22, p. 3092–3097.

2. Berlanda, N., Somigliana, E., Frattaruolo, MP., et al. Surgery versus hormonal therapy for deep endometriosis: is it a choice of the physician? Eur J Obstet Gynecol Reprod Biol, 2017, 209, p. 67–71.

3. Biberoglu, KO., Behrman, SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol, 1981, 139, p. 645–654

4, Caruso, S., Iraci, M., Cianci, S., et al. Quality of life and sexual function of women affected by endometriosis-assotiated pelvic pain when treated by dienogest. J Endocrinol Invest, 2015, 38, p. 1211–1218.

5. Fedele, L., Bianchi, S., Zanconato, G., et al. Long-term follow-up after conservative surgery of rectovaginal endometriosis. Am J Obstet Gynecol, 2004, 190, p. 1020–1024.

6. Ferrero, S., Alessandri, F., Racca, A., et al. Treatment of pain associated with deep endometriosis: alternatives and evidence. Fertil Steril, 2015, 104, p. 771–792.

7. Guerriero, S., Ajossa, S., Orozco, R., et al. Diagnostic accuracy of transvaginal ultrasound for diagnosis of deep endometriosis in the recto-sigmoid: a metaanalysis. Ultrasound Obset Gynecol, 2016, 47, p. 281–289.

8. Lee, JH., Song, JY., Yi, KW., et al. Effectivness of dienogest for treatment of recurrent endometriosis: multicenter data. Reprod Sci, 2018, 25, p. 1515–1522.

9. Legendre, G., Dellbos, l., Hudon, E., et al. New medical treatments for painful endometriosis: CNGOF-HAS H endometriosis guidelines. Gynecol Obstet Fertil Senol, 2018, 46, p. 256–263.

10. Leonardo-Pinto, JP., Benetti-Pinto, CL., Cursino, K., et al. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynaec Reprod Biol, 2017, 211, p. 108–111.

11. Morotti, M., Sozzi, F., Remorgida, V., et al. Dienogest in women with persistent endometriosis – related pelvic pain during noretistherone acetate treatment. Eur J Obstet Gynecol Reprod Biol, 2014, 183, p. 188–192.

12. Römer, T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet, 2018, 298, p. 747–753.

13. Schindler, AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health, 2011, 3, 175–184.

14. Strowitzki, T., Marr, J., Gerlinger, C., et al. Dienogestis as affective as leuprolideacetate in treating the painful symptoms of endometriosis: a 24 week, randomized, multicentre, open-label trial. Hum Reprod, 2010, 25, p. 633–641.

15. Taylor, HS., Adamson, GD., Diamond, MP., et al. An evidence-based approach to assessing surgical versus clinical diagnosis of symptomatic endometriosis. Int J Gynaecol Obstet, 2018, 142, p. 131–142.

16. Ulrich, U., Buchweitz, O., Greb, R., et al. National German Guideline: Guideline for the Diagnosis and Treatment of Endometriosis. Geburtshilfe Frauenheilkd, 2014, 74, p. 1104–1118.

17. Vercellini, P., Somigliana, E., Consonni, D., et al. Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod, 2012, 27, p. 3450–3459.